[1] |
George C, Deroide F, Rustin M. Pyoderma gangrenosum ⁃a guide to diagnosis and management[J]. Clin Med (Lond), 2019,19(3):224⁃228. doi: 10.7861/clinmedicine.19⁃3⁃224.
|
[2] |
Maverakis E, Le ST, Callen J, et al. New validated diagnostic criteria for pyoderma gangrenosum[J]. J Am Acad Dermatol, 2019,80(4):e87⁃e88. doi: 10.1016/j.jaad.2018.08.068.
|
[3] |
Townsend T, Probert C. Editorial: peristomal pyoderma gangrenosum⁃a challenge for patients, healthcare professionals and research[J]. Aliment Pharmacol Ther, 2020,52(2):404⁃405. doi: 10.1111/apt.15822.
|
[4] |
Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum[J]. Nat Rev Dis Primers, 2020,6(1):81. doi: 10.1038/s41572⁃020⁃0213⁃x.
|
[5] |
Plumptre I, Knabel D, Tomecki K. Pyoderma gangrenosum: a review for the gastroenterologist[J]. Inflamm Bowel Dis, 2018,24(12):2510⁃2517. doi: 10.1093/ibd/izy174.
|
[6] |
Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes[J]. N Engl J Med, 2018,378(12):1132⁃1141. doi: 10.1056/NEJMra1713301.
|
[7] |
Chandrakasan S, Venkateswaran S, Kugathasan S. Nonclassic inflammatory bowel disease in young infants: immune dysregulation, polyendocrinopathy, enteropathy, X⁃linked syndrome, and other disorders[J]. Pediatr Clin North Am, 2017,64(1):139⁃160. doi: 10.1016/j.pcl.2016.08.010.
|
[8] |
Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment[J]. Expert Rev Clin Immunol, 2018,14(3):225⁃233. doi: 10.1080/1744666X.2018.1438269.
|
[9] |
Goldust M, Hagstrom EL, Rathod D, et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J]. Expert Rev Clin Pharmacol, 2020,13(2):157⁃161. doi: 10.1080/17512433.2020.1709825.
|